Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncology In 21st Century Cures: Heading Toward A Two-FDA Solution?

Executive Summary

The 21st Century Cures Act regulatory reform provisions amount to a lot of little things: tweaks to encourage ongoing activities rather than bold departures at a time when the overall regulatory climate is good for innovators. But the law could also be the start of something bigger – a more formal division within the US FDA between oncology and everything else.


Related Content

US FDA Commissioner Search: Pharma’s Preferred Candidate Is Gottlieb
CDER’s 50 Open Leadership Posts Could Be Bigger Hiring Challenges After Trump Freeze
Multiple ‘Centers of Excellence’ At US FDA Could Create Review Inefficiencies – Jenkins
The Real Impact Of ‘Cures’: The Hype Means Something
Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?
FDA's Pazdur Won't Become Oncology Bureaucrat: 'My Presence Will Be Felt'





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts